The reimbursement model changed; the audit risk did not
CMS changed the Medicare payment methodology for most skin substitute products beginning in 2026, moving them into an incident-to supply framework in covered application procedures. That payment shift did not eliminate the need to prove medical necessity, coverage, accurate units, appropriate product use, and a defensible clinical record. See the CMS CY 2026 Physician Fee Schedule final rule.
For practices that built large wound care service lines around high-cost products, the current environment demands tighter documentation, tighter product reconciliation, and a more disciplined response when an audit arrives.






